REGENXBIO Files 8-K on Shareholder Votes and Financials
Ticker: RGNX · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1590877
Sentiment: neutral
Topics: corporate-governance, financial-reporting
TL;DR
REGENXBIO filed an 8-K for shareholder votes & financials. Check it out.
AI Summary
On May 31, 2024, REGENXBIO Inc. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The filing includes information related to their business operations and corporate governance, with the company's principal executive offices located at 9804 Medical Center Drive, Rockville, Maryland.
Why It Matters
This filing provides an update on REGENXBIO's corporate actions, including shareholder voting matters and financial reporting, which are crucial for investors to understand the company's governance and financial health.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate governance and financial reporting, not indicating any immediate operational or financial distress.
Key Players & Entities
- REGENXBIO Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
- 9804 Medical Center Drive, Rockville, Maryland 20850 (location) — Principal Executive Offices
- 240 552-8181 (phone_number) — Registrant's Telephone Number
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the provided text.
What financial statements and exhibits are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific content of these statements and exhibits is not detailed in the provided text.
When was REGENXBIO Inc. incorporated?
REGENXBIO Inc. was incorporated in Delaware, as indicated by the filing.
What is REGENXBIO Inc.'s IRS Employer Identification Number?
REGENXBIO Inc.'s IRS Employer Identification Number is 47-1851754.
What is the SIC code for REGENXBIO Inc.?
The Standard Industrial Classification (SIC) code for REGENXBIO Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 573 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2024-06-03 16:35:10
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Se
Filing Documents
- rgnx-20240531.htm (8-K) — 51KB
- 0000950170-24-068050.txt ( ) — 159KB
- rgnx-20240531.xsd (EX-101.SCH) — 23KB
- rgnx-20240531_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. REGENXBIO Inc. (the "Company") held its Annual Meeting on May 31, 2024. The final voting results for each proposal considered at the Annual Meeting are set forth below. For more information on the proposals, see the Company's definitive proxy statement on Schedule 14A filed with the SEC on April 4, 2024 (the "Proxy Statement"). Proposal 1 : By the following vote, the following three persons were elected to serve as Class III directors until the Company's 2027 annual meeting of stockholders: Nominee Votes For Votes Withheld Broker Non-Votes George Migausky 39,124,767 1,785,552 3,342,209 Kenneth T. Mills 39,258,562 1,651,757 3,342,209 David C. Stump 35,039,630 5,870,689 3,342,209 Proposal 2 : By the following vote, the stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024: Votes For Votes Against Votes Abstaining Broker Non-Votes 44,152,900 58,293 41,335 0 Proposal 3 : By the following vote, the stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement: Votes For Votes Against Votes Abstaining Broker Non-Votes 40,147,111 727,846 35,362 3,342,209
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REGENXBIO INC. Date: June 3, 2024 By: /s/ Patrick J. Christmas II Patrick J. Christmas II Executive Vice President, Chief Legal Officer